The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Understanding myeloma disease dissemination: are CTCs responsible?
Circulating tumor cells (CTCs) in multiple myeloma (MM) are low in frequency, and it has been hypothesized that just a few of these cells disseminate the disease through the peripheral blood. Here, Bruno Paiva, PhD, of the University of Navarra, Pamplona, Spain, presents the results of his group’s work on the transcriptional profiling of CTCs in MM, in order to investgate this hypothesis. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
